Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years

Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years

Background: This phase 3, multi-center, open-label study evaluated the immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM, Menveo®; Novartis Vaccines and Diagnostics S.r.l., Siena, Italy) in healthy Indian subjects aged 2–75 years, to provide data for licensure...

Full description

Bibliographic Details
Main Authors: Sanjay Lalwani, Sharad Agarkhedkar, Nithya Gogtay, Sonali Palkar, Shalaka Agarkhedkar, Urmila Thatte, Hoshang Vakil, Rekha Jonnalagedda, Paola Pedotti, Margaret Hoyle, Chiranjiwi Bhusal, Ashwani Arora
Format: Article
Language:English
Published: Elsevier 2015-09-01
Series:International Journal of Infectious Diseases
Subjects:
Meningococcal disease
Quadrivalent vaccine
CRM197 conjugate
Immunogenicity
Safety
India
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971215001708

Internet

http://www.sciencedirect.com/science/article/pii/S1201971215001708

Similar Items